The new use is the third for Kymriah (tisagenlecleucel) in the EU and offers patients with grade 1, 2 and 3A follicular lymphoma that has returned after two or more prior treatments a new ...

Pfizer’s Adcetris combination regimen gets US FDA approval to treat relapsed/refractory diffuse large B-cell lymphoma: New York Friday, February 14, 2025, 11:00 Hrs [IST] Pfizer ...

After an apparent accidental early release, Pfizer has revealed phase 1 data showing its investigational candidate, alongside ...

Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application ...

NEW YORK, NY, USA I 12, 2025 I Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental ...

Micrograph of a diffuse large B cell lymphoma, AbbVie and partner Genmab have FDA approval for the lead drug in their $3.9 billion cancer ... strength of the phase 1/2 EPCORE study, which showed ...

The descriptive term AtLP may be used as an interim label when morphologic and molecular features are not sufficient to render a positive diagnosis of lymphoma. The development of AtLP may also ...

Galapagos NV (Euronext & NASDAQ: GLPG), a global biotechnology company dedicated to transforming patient outcomes through life-changing science and innovation, today reported its financial results for ...

Nintendo Switch 2 is finally confirmed. After literal years of unverified rumors, dubious leaks and copious amounts of online speculation, Nintendo has lifted the lid on its next-generation ...

The CHMP based its green light on results from the combo’s phase 3 ... follicular lymphoma (FL) who’ve previously tried two or more systemic therapies. BMS used data from its phase 2 TRANSCEND ...

When is the Ark 2 release date? Ever since the Ark 2 announcement at The Game Awards 2020, we’ve been looking forward to learning more about the upcoming dinosaur-themed survival game.